Quantitative Radiology Solutions (QRS) has launched a multi-center clinical evaluation of its Automatic Anatomy Recognition (AAR) software for radiation treatment planning and has received its initial patient studies from the New York Proton Center (NYPC) in New York City.
The clinical evaluation is one of the primary aims of the STTR Phase 2 grant QRS received from the National Cancer Institute. The endpoints of the evaluation include verifying the accuracy, efficiency, and clinical acceptability of the AAR-generated contours for treatment planning. Three additional sites will start submitting data in the coming months. Upon regulatory clearance, QRS will be able to generate revenue with the first product release of AAR in the U.S.
“We are excited to collaborate with Dr. Charles Simone, Chief Medical Officer, Dr. Isabelle Choi, Director of Research, and the entire team at the New York Proton Center’s new facility in East Harlem. NYPC is partnered with leading academic medical centers Memorial Sloan Kettering Cancer Center, Montefiore Medical Center, and Mount Sinai Health System, making it the ideal partner to help QRS evaluate its deep learning based artificial intelligence algorithms in a clinical setting,” said Steven Owens, Chief Technology & Operating Officer for QRS.
“Our team is dedicated to providing the gold standard of proton therapy. Innovative AI-powered radiation treatment software solutions like AAR can better enable us to accomplish that goal,” said Dr. Charles Simone, Chief Medical Officer of the New York Proton Center. “We are extremely thrilled about the potential of the QRS technology to improve clinical outcomes for our patients. This National Institutes of Health-funded initiative is one of the first of many exciting cutting-edge projects to come to NYPC.”
“Enhancing treatments with new insights from clinical studies is central to our mission at NYPC. We are excited to be the first center to pioneer this impactful work with QRS and to be leading a federally funded research project within just months of the opening of our center,” said Dr. Isabelle Choi, Director of Research at the New York Proton Center. “Our evaluation of AAR efficacy in a treatment setting has been an auspicious early addition to the extensive proton therapy research program we are building at NYPC, which we expect in short order to be one of the largest and most comprehensive in the U.S.”
About the New York Proton Center: The New York Proton Center is creating the gold standard for proton therapy, giving new hope to patients living with cancer. In partnership with leading academic medical centers—Memorial Sloan Kettering Cancer Center, Montefiore Medical Center, Mount Sinai Health System, and ProHEALTH as a managing partner—the New York Proton Center brings together expert oncologists, clinical care teams, and researchers to improve cancer care and advance the clinical evidence for proton therapy.
www.nyproton.com